Yuhan Corporation has signed a memorandum
of understanding with Syntekabio to promote joint research on discovering
biological markers and new drugs
As per reports from a leading South Korean
daily, the country’s leading pharmaceutical firm Yuhan Corporation has
collaborated with bio-informatics company Syntekabio to develop new drugs using
genomic big data and an artificial intelligence (AI) platform.
The news report read that Yuhan Corporation
has signed a memorandum of understanding with Syntekabio to promote joint
research on discovering biological markers or indicators of certain biological
condition by analyzing patients’ genome properties and searching for new drug
candidate materials using an AI-based platform.
Syntekabio was founded in 2009 firm owns
platform technology that analyzes genomic big data related to cancer and other
rare diseases, and manages a prediction platform for anti-cancer drug response
applied with deep learning technology. It has developed an algorithm that
discovers biomarkers concerned with drug responses by linking genome big data
and AI technology.
The deal is expected to help Yuhan to
reduce on the cost and period needed for new drug development by using genomic
big data-based AI platform. Earlier, Korea Pharmaceutical and Bio-Pharma
Manufacturers Association had announced that it will establish an AI-based new
drug development support center to boost the high technology sector in the
pharmaceutical industry. The center will be supported by 17 members including
the association, Korea Health Industry Development Institute, AI developers,
and pharmaceutical companies such as Hanmi Pharm Co., Yuhan Corporation, Green
Cross Corp., and Chong Kun Dang Pharmaceutical Corp.
